Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval.
The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company's Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.
Experienced team with a global track record based in key life science hubs in China and the US.
We are determined to address critical unmet medical needs of patients.